Skip to content
You are now leaving to visit

Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases

Transaction valued at up to $760 million, including $75 million upfront payment, plus royalties up to 20% Planned Phase 2 program to begin in early 2019 CARLSBAD, Calif. , Oct. 10, 2018 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced a new collaboration with Roche to